论文部分内容阅读
目的:探讨结核分枝杆菌eis基因突变与氨基糖苷耐药之间的相互关系。方法:以本室保存的35株已确定耐一线药物(异烟肼、利福平、乙胺丁醇、链霉素)的结核分支杆菌为研究对象,应用BECTEC960测定其二线药物(阿米卡星、卡那霉素)的耐药情况,同时应用基因测序的方法测定结核分枝杆菌eis基因突变情况,分析eis基因突变与氨基糖苷耐药之间的相互关系。结果:氨基糖苷耐药的部分结核分杆杆菌中,eis基因487位碱基出现突变,相应的163位氨基酸密码子由CGT突变为CAT,即由缬氨酸变为异亮氨酸。结论:eis基因V163I突变(缬氨酸变为异亮氨酸)可能与结核分枝杆菌耐氨基糖苷类药物有关。
Objective: To explore the relationship between mutations of eis gene of Mycobacterium tuberculosis and aminoglycoside resistance. Methods: Thirty-five Mycobacterium tuberculosis strains of first-line drugs (isoniazid, rifampicin, ethambutol and streptomycin) were collected from our laboratory. The second-line drugs (Amikacs Kanamycin, kanamycin, kanamycin, kanamycin, kanamycin, kanamycin, kanamycin and kanamycin). RESULTS: In the aminoglycoside-resistant part of Mycobacterium tuberculosis, the 487th base of eis gene was mutated and the corresponding 163th amino acid codon was changed from CGT to CAT, that is, from valine to isoleucine. Conclusion: The eis gene V163I mutation (valine to isoleucine) may be related to Mycobacterium tuberculosis resistance to aminoglycosides.